title: Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.
abstract: Although well established for the treatment of certain hematologic malignancies, maintenance therapy has only recently become a treatment paradigm for advanced non-small-cell lung cancer. Maintenance therapy, which is designed to prolong a clinically favorable state after completion of a predefined number of induction chemotherapy cycles, has two principal paradigms. Continuation maintenance therapy entails the ongoing administration of a component of the initial chemotherapy regimen, generally the nonplatinum cytotoxic drug or a molecular targeted agent. With switch maintenance (also known as sequential therapy), a new and potentially non-cross-resistant agent is introduced immediately on completion of first-line chemotherapy. Potential rationales for maintenance therapy include increased exposure to effective therapies, decreasing chemotherapy resistance, optimizing efficacy of chemotherapeutic agents, antiangiogenic effects, and altering antitumor immunity. To date, switch maintenance therapy strategies with pemetrexed and erlotinib have demonstrated improved overall survival, resulting in US Food and Drug Administration approval for this indication. Recently, continuation maintenance with pemetrexed was found to prolong overall survival as well. Factors predicting benefit from maintenance chemotherapy include the degree of response to first-line therapy, performance status, the likelihood of receiving further therapy at the time of progression, and tumor histology and molecular characteristics. Several aspects of maintenance therapy have raised considerable debate in the thoracic oncology community, including clinical trial end points, the prevalence of second-line chemotherapy administration, the role of treatment-free intervals, quality of life, economic considerations, and whether progression-free survival is a worthy therapeutic goal in this disease setting.
authors: Division of Hematology-Oncology, Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA. joan.schiller@utsouthwestern.com
authors: David E
authors: DE
authors: Gerber
authors: Joan H
authors: JH
authors: Schiller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D060046:Maintenance Chemotherapy / Q000191:economics / Q000379:methods; D015201:Meta-Analysis as Topic; D011788:Quality of Life
references: J Clin Oncol. 2007 Nov 20;25(33):5233-9
references: 18024869
references: Nat Clin Pract Oncol. 2006 Aug;3(8):406-7
references: 16894366
references: J Clin Oncol. 2001 Feb 15;19(4):1195-206
references: 11181686
references: Lung Cancer. 2004 Feb;43(2):183-94
references: 14739039
references: J Clin Oncol. 2000 Jun;18(12):2354-62
references: 10856094
references: J Thorac Oncol. 2010 Aug;5(8):1111-2
references: 20661082
references: J Clin Oncol. 2009 Feb 1;27(4):591-8
references: 19075278
references: Lancet. 2009 May 2;373(9674):1525-31
references: 19410716
references: J Clin Oncol. 2008 May 20;26(15):2450-6
references: 18378568
references: J Clin Oncol. 2010 Feb 20;28(6):911-7
references: 20100966
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: J Thorac Oncol. 2011 Feb;6(2):365-71
references: 21173713
references: J Clin Oncol. 2001 Mar 1;19(5):1336-43
references: 11230476
references: Am J Med Sci. 2007 Apr;333(4):221-5
references: 17435415
references: J Clin Oncol. 2009 Jul 10;27(20):3277-83
references: 19470938
references: Cancer Treat Rep. 1986 Jan;70(1):163-9
references: 3510732
references: J Clin Oncol. 1991 Nov;9(11):2002-15
references: 1941059
references: Lung Cancer. 2012 Jul;77(1):224-31
references: 22369719
references: Cancer Treat Rev. 2010 Nov;36 Suppl 3:S42-5
references: 21129609
references: J Clin Oncol. 2006 Oct 10;24(29):4721-30
references: 16966690
references: N Engl J Med. 2006 Dec 14;355(24):2542-50
references: 17167137
references: J Thorac Oncol. 2012 Aug;7(8):1291-5
references: 22659963
references: Lancet. 2003 Feb 8;361(9356):457-64
references: 12583944
references: N Engl J Med. 1991 Nov 7;325(19):1342-8
references: 1922236
references: J Clin Oncol. 2003 Jul 1;21(13):2460-5
references: 12829663
references: Eur J Cancer. 2009 Mar;45(4):601-7
references: 19111457
references: Clin Cancer Res. 2007 Sep 1;13(17):5150-5
references: 17785570
references: Cancer Immunol Immunother. 2009 Oct;58(10):1627-34
references: 19221744
references: J Clin Oncol. 2007 Apr 20;25(12):1545-52
references: 17442998
references: Gynecol Oncol. 2011 Sep;122(3):473-8
references: 21665250
references: BMJ. 1998 Sep 19;317(7161):771-5
references: 9740561
references: Ann Oncol. 2010 Sep;21(9):1804-1809
references: 20150572
references: Cancer. 2005 Dec 15;104(12):2650-7
references: 16284984
references: Chest. 2011 Jul;140(1):117-126
references: 21436247
references: J Clin Oncol. 2011 Nov 1;29(31):4113-20
references: 21969500
references: J Natl Cancer Inst. 2005 Apr 6;97(7):499-506
references: 15812075
references: J Clin Oncol. 2005 Sep 20;23(27):6674-81
references: 16170175
references: Cancer Cell. 2008 Sep 9;14(3):195-6
references: 18772108
references: J Clin Oncol. 2008 Dec 10;26(35):5755-60
references: 19001323
references: Cancer Treat Rep. 1977 Oct;61(7):1307-17
references: 589597
references: Lancet Oncol. 2012 May;13(5):466-75
references: 22512843
references: J Thorac Oncol. 2010 Aug;5(8):1263-72
references: 20581708
references: J Clin Oncol. 2012 Apr 1;30(10):1030-3
references: 22370321
references: Lancet. 2011 Jan 1;377(9759):42-51
references: 21176949
references: J Clin Oncol. 2005 Sep 1;23(25):5892-9
references: 16043829
references: N Engl J Med. 2011 Dec 29;365(26):2473-83
references: 22204724
references: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references: 19188680
references: J Clin Oncol. 2003 Aug 1;21(15):2933-9
references: 12885812
references: N Engl J Med. 2011 Dec 29;365(26):2484-96
references: 22204725
references: J Clin Oncol. 2010 Feb 10;28(5):753-60
references: 20038730
references: J Natl Cancer Inst. 2011 Dec 7;103(23):1799-806
references: 22021664
references: J Clin Oncol. 2004 Mar 1;22(5):785-94
references: 14990633
references: J Clin Oncol. 2000 May;18(10):2095-103
references: 10811675
references: Patient Educ Couns. 2012 Oct;89(1):102-8
references: 22632736
references: N Engl J Med. 2012 May 10;366(19):1770-81
references: 22571201
references: Lung Cancer. 2012 Aug;77(2):331-8
references: 22546678
references: J Clin Oncol. 2012 Oct 1;30(28):3516-24
references: 22949150
references: Ann Oncol. 2007 Jun;18(6):1037-42
references: 17404152
references: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references: 18506025
references: Lung Cancer. 2012 Jun;76(3):465-71
references: 22153602
references: J Clin Oncol. 2002 Mar 1;20(5):1335-43
references: 11870177
references: Lancet Oncol. 2012 Mar;13(3):292-9
references: 22336221
references: J Thorac Oncol. 2010 Apr;5(4):540-5
references: 20195170
references: Lancet Oncol. 2010 Jun;11(6):521-9
references: 20493771
references: Eur J Cancer. 2011 Oct;47(15):2331-40
references: 21802939
references: Cancer Res. 2003 Aug 1;63(15):4342-6
references: 12907602
references: J Clin Oncol. 2013 Nov 1;31(31):3926-34
references: 24101054
references: Cancer Immunol Immunother. 2007 May;56(5):641-8
references: 16960692
references: Value Health. 2009 Jan-Feb;12(1):80-7
references: 19911442
references: Br J Cancer. 2006 Oct 23;95(8):966-73
references: 17047644
references: Lancet. 2009 Oct 24;374(9699):1432-40
references: 19767093
references: Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33
references: 526911
references: J Clin Oncol. 2004 Mar 1;22(5):777-84
references: 14990632
references: Lancet. 1996 Jun 29;347(9018):1783-8
references: 8667921
references: Lancet Oncol. 2012 Mar;13(3):247-55
references: 22341744
references: J Clin Oncol. 1999 Oct;17(10):3188-94
references: 10506617
references: Lung Cancer. 1998 Feb;19(2):141-51
references: 9567251
references: J Clin Oncol. 2004 May 1;22(9):1589-97
references: 15117980
references: Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(4):251-6
references: 1702913
references: Lung Cancer. 2006 May;52(2):155-63
references: 16569462